Actively Recruiting
Phase 1 Study of N-Acetylcysteine for Patients With the m.3243A>G Mutation and Low Brain Glutathione Levels Evaluating Safety and Effects on Brain and Motor Function
Led by Michio Hirano, MD · Updated on 2026-01-23
18
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying the effects of N-Acetylcysteine NAC, an antioxidant, on patients with the m.3243A>G mitochondrial mutation who often have low brain glutathione levels. This condition may impair the brains ability to repair damage caused by toxic chemicals related to the mitochondrial disorder. The study aims to assess how NAC affects brain glutathione levels, cognitive skills, motor skills, and overall quality of life. Participants will receive NAC in a dose escalation format, starting with 18 individuals taking either 1800, 3600, or 5400 mg per day, divided into three daily doses, over three months. The study will first determine if the 3600 mg dose is safe and shows potential effectiveness. If it is safe, further participants will receive 5400 mg per day if not, the lower 1800 mg dose will be used. This pilot study helps identify the safest and most effective NAC dose for future trials. During the study, participants will be monitored over four months to assess the maximum tolerated dose of NAC, changes in neurological and cognitive function, motor capacity using a 6-minute walk test, performance scale scores, and brain glutathione levels. Researchers will use magnetic resonance spectroscopic imaging MRSI and various clinical assessments to evaluate these outcomes, ensuring close observation of safety and treatment effects throughout the trial.
CONDITIONS
Brief Title
Study of N-acetylcysteine in the Treatment of Patients With the m.3243A>G Mutation and Low Brain Glutathione Levels
Research Team
K
Kris Engelstad, MS, CGC
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here